Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Nov;52(11):e13855.
doi: 10.1111/eci.13855. Epub 2022 Sep 7.

Liver fibrosis scores and prognosis in patients with cardiovascular diseases: A systematic review and meta-analysis

Zhiwei Yan  1 , Yang Liu  2 , Wei Li  1 , Xiaopeng Zhao  1 , Weichun Lin  3 , Jing Zhang  2 , Shuchun Yu  2 , Jianyong Ma  4 , Jingfeng Wang  3   5 , Peng Yu  6 , Weiguang Li  7 , Xiao Liu  3   5
Affiliations
Meta-Analysis

Liver fibrosis scores and prognosis in patients with cardiovascular diseases: A systematic review and meta-analysis

Zhiwei Yan et al. Eur J Clin Invest. 2022 Nov.

Abstract

Background: In patients with nonalcoholic fatty liver disease, liver fibrosis was associated with a higher risk of cardiovascular events. However, the relationship between liver fibrosis scores and clinical outcomes in patients with cardiovascular disease remains unclear.

Methods: Searching from PubMed, EMBASE and Cochrane Library databases yielded cohort studies that reported adjusted effect size between liver fibrosis scores (Fibrosis-4 score [FIB-4] or NAFLD fibrosis score [NFS]) and prognosis in patients with cardiovascular disease. The effect size was computed using a random-effects model.

Results: This meta-analysis included twelve cohort studies involving 25,252 patients with cardiovascular disease. Participants with the highest baseline level of FIB-4 or NFS had a significantly increased risk of cardiovascular events (FIB-4, HR: 1.75, 95% CI: 1.53-2.00, I 2 = 0%; NFS, HR: 1.92, 95% CI: 1.50-2.47, I 2 = 47%). This finding was consistent with the analysis of FIB-4 or NFS as a continuous variable (per 1-unit increment FIB-4, HR: 1.15, 95% CI: 1.06-1.24, I 2 = 72%; NFS, HR: 1.15, 95% CI: 1.07-1.24, I 2 = 71%). Furthermore, participants with the highest levels of FIB-4 or NFS had a greater risk of cardiovascular mortality (FIB-4, HR: 2.07, 95% CI: 1.19-3.61, I 2 = 89%; NFS, HR: 3.72, 95% CI: 2.62-5.29, I 2 = 60%) and all-cause mortality (FIB-4, HR: 1.81, 95% CI: 1.24-2.66, I 2 = 90%; NFS, HR: 3.49, 95% CI: 2.82-4.31, I 2 = 25%). This result was also consistent as a continuous variable.

Conclusion: Higher levels of FIB-4 and NFS are related to an increased risk of cardiovascular events, cardiovascular mortality and all-cause mortality in patients with cardiovascular disease.

Keywords: NAFLD fibrosis score; cardiovascular disease; fibrosis-4 score; liver fibrosis; meta-analysis.

PubMed Disclaimer

References

REFERENCES

    1. Virani SS , Alonso A , Benjamin EJ , et al. Heart disease and stroke Statistics-2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139-e596.
    1. Manne V , Handa P , Kowdley KV . Pathophysiology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Clin Liver Dis. 2018;22(1):23-37.
    1. Rinella ME . Non-alcoholic fatty liver disease: a systematic review. JAMA. 2015;313(22):2263-2273.
    1. Wang XJ , Malhi H . Nonalcoholic fatty liver disease. Ann Intern Med. 2018;169(9):Itc65-itc80.
    1. Simon TG , Corey KE , Cannon CP , et al. The non-alcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. Int J Cardiol. 2018;270:245-252.

MeSH terms

Substances

LinkOut - more resources